RT Journal Article SR Electronic T1 BCG vaccine derived peptides induce SARS-CoV-2 T cell cross-reactivity JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2020.11.21.20236018 DO 10.1101/2020.11.21.20236018 A1 Peter J. Eggenhuizen A1 Boaz H. Ng A1 Janet Chang A1 Ashleigh L. Fell A1 Wey Y. Wong A1 Poh- Yi Gan A1 Stephen R. Holdsworth A1 Joshua D. Ooi YR 2020 UL http://medrxiv.org/content/early/2020/11/23/2020.11.21.20236018.abstract AB Epidemiological studies suggest that the Bacillus Calmette-Guérin (BCG) vaccine may have protective effects against coronavirus disease 2019 (COVID-19); and, there are now more than 15 ongoing clinical trials seeking to determine if BCG vaccination can prevent or reduce the severity of COVID-19 (1). However, the mechanism by which BCG vaccination can induce a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) specific T cell response is unknown. Here, in silico, we identify 8 BCG derived peptides with significant sequence homology to either SARS-CoV-2 NSP3 or NSP13 derived peptides. Using an in vitro co-culture system, we show that human CD4+ and CD8+ T cells primed with a BCG derived peptide developed enhanced reactivity to its corresponding SARS-CoV-2 derived peptide. As expected, HLA differences between individuals meant that not all persons developed immunogenic responses to all 8 BCG derived peptides. Nevertheless, all of the 20 individuals that were primed with BCG derived peptides developed enhanced T cell reactivity to at least 7 of 8 SARS-CoV-2 derived peptides. These findings provide a mechanistic basis for the epidemiologic observation that BCG vaccination confers protection from COVID-19; and supports the use of BCG vaccination to induce cross-reactive SARS-CoV-2 specific T cell responses.Competing Interest StatementDr. Ooi reports grants from Monash Health Foundation, during the conduct of the study; no financial relationships with any organizations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.Funding StatementDr. Ooi reports grants from Monash Health Foundation during the conduct of the study. No other payments or services from a third party were received at any time for any aspect of the submitted work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Monash University Human Research Ethics Committee project ID 25834.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesCorrespondence and requests for materials should be addressed to Dr. Ooi.